From the chemistry of Epoxy-Sugar nucleosides to the discovery of Anti-HIV Agent 4'-ethynylstavudine-Festinavir

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1880-1897

  Haraguchi, Kazuhiro ^a   Takeda, Shingo ^a   Kubota, Yutaka ^a   Kumamoto, Hiroki ^a   Tanaka, Hiromichi ^a   Hamasaki, Takayuki ^b   Baba, Masanori ^b   Paintsil, Elijah ^c   Cheng, Yung Chi ^c  

^a SHOWA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HIV 1 agent; Epoxide; NRTIs; Nucleoside; Organoaluminum reagent; Stavudine; Sugar

Indexed keywords

ALUMINUM; ANTIVIRUS AGENT; FESTINAVIR; LAMIVUDINE; MITOCHONDRIAL DNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE DERIVATIVE; SILICON; STAVUDINE; SUGAR; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CHEMICAL BOND; CYTOTOXICITY; DNA SYNTHESIS; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; REVIEW; RING OPENING; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG DISCOVERY; EPOXY COMPOUNDS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOSIDES; STAVUDINE;

EID: 84876712884     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319100011     Document Type: Review

References (63)

1. Global report: UNAIDS report on the global AIDS endemic 2010. http://www.unaids.org/globalreport/global_report.htm. Accessed on 02/11/2012.
2. Tan JJ, Chong XJ, Hu LM, Wang CX, Jia L, Liang XL. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov. Today 2010; 15(5/6): 186-97.
3. Matsuda A. Recent development of anti-HIV nucleosides. J Synth Org Chem Jpn 1990; 48(10): 907-20.
4. Ichikawa E, Kato K. Sugar-modified nucleosides in past 10 years, a review. Current Medicinal Chemistry 2001; 8(4): 385-423.
5. Huryn DM, Okabe M. AIDS-driven nucleoside chemistry. Chem Rev 1992; 92(8): 1745-68.
6. De Clercq E. The design of drugs for HIV and HCV. Nature Review 2007; 6: 1001-18.
7. McCarthy JR Jr, Robins RK, Robins MJ. Purine nucleosdes. XXII. synthesis of angustmycin A (decoynine) and related unsaturated nucleosides. J Am Chem Soc 1968; 90(17): 4993-9.
8. Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A. Nucleosides and Nucleotides. 158. 1-(3-C-Ethynyl----D-ribo-pentofuranosyl) cytosine, 1-(3-C-ethynyl----D-ribo-pentofuranosyl)uracil and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 1996; 39(25): 5005-11.
9. O-Yang C, Wu HY, Fraser-Smith EB, Walker KAM. Synthesis of 4β-cyanothymidine and analogs as potent inhibitors of HIV. Tetrahedron Lett 1992; 33(1): 37-40.
10. Itoh Y, Haraguchi K, Tanaka H, Gen E, Miyasaka T. Divergent and stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position. J Org Chem 1995; 60(3): 656-62.
11. Kodama T, Shuto S, Ichikawa S, Matsuda A. A highly stereoselective samarium diiodide-promoted aldol reaction with 1β-phenylseleno-2β-keto nucleosides. synthesis of 1β----branched uridine derivative. J Org Chem 2002; 67(22): 7706-15.
12. Haraguchi K, Itoh Y, Matsumoto K, Nakamura KT, Tanaka H. Stereoselective synthesis of 1β-C-branched arabinofuranosyl nucleosides via anomeric radicals generated by 1,2-acyloxy migration. J Org Chem. 2003; 68(5): 2006-9.
13. Kumamoto H, Murasaki M, Haraguchi K, Tanaka H. Nucleophilic addition of benzenethiol to 1β,2β-unsaturated nucleosides: 1β-Cphenylthio-2β-deoxynucleosides as anomeric radical precursors. J Org Chem. 2002; 67(17): 6124-30.
14. Kodama T, Shuto S, Nomura M, Matsuda, A. An efficient method for the preparation of 1β-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1β-substituted ribonucleosides. Chem Eur J 2001; 7(12): 2332-40.
15. Sugimoto I, Shuto S, Mori S, Shigeta S, Matsuda A. Nucleosides and nucleotides. 183. synthesis of 4β-branched thymidines as a new type of antiviral agent. Bioorg Med Chem Lett.1999; 9(3): 385-8.
16. For a review, see: Smith JG. Synthetically useful reactions of epoxides. Synthesis 1984; 629-56.
17. Ashwell M, Jones AS, Walker RT. The synthesis of some branched-chain-sugar nucleoside analogues. Nucleic Acids Res 1987; 15(5): 2157-66.
18. Adam W, Balas J, Hadjarapoglou L. A convenient preparation of acetone solution of dimethyldioxirane., Chem Ber 1991; 124(10): 2377.
19. Curci R, Fiorentiono M, Troisi L, Edwards JO, Pater RH. Epoxidation of alkenes by dioxirane intermediates generated in the reaction of potassium caroate with ketones. J Org Chem 1980; 45(23): 4758-60.
20. Murray RW, Jeyaman R. Dioxiranes: synthesis and reaction of methyldioxiranes. J Org Chem 1985; 50(16): 2847-53.
21. Haraguchi K, Kubota Y, Tanaka H. Ring opening of nucleoside 1',2'-epoxides with organoaluminum reagents: stereoselective entry to ribonucleosides branched at the anomeric position. J Org Chem 2004; 69(6): 1831-6.
22. Haraguchi K, Konno K, Yamada K, Kitagawa Y, Nakamura KT, Tanaka H. Electrophilic glycosidation employing 3,5-O-(di-tertbutylsilylene)-erythro-furanoid glycal leads to exclusive formation of the α-anomer: synthesis of 2β-deoxynucleosides and its 1β-branched analogues. Tetrahedron 2010; 66(25): 4587-600.
23. Kubota Y, Haraguchi K, Kunikata M, Hayashi M, Ohkawa M, Tanaka H. Anti versus syn opening of epoxides derived from 9-(3-deoxy-dd-D-glycero-pento-3-enofuranosyl)adenine with Me3Al: factors controlling the stereoselectivity. J Org Chem 2006; 71(3): 1099-103.
24. Maag H, Rydzewski RM, McRoberts MJ, Crawford-Ruth D, Verheyden JPH, Prisbe EJ. Synthesis and anti-HIV activity of 4β-azidoand 4β-methoxynucleosides. J Med Chem 1992; 35(8): 1440-51.
25. O-Yang C, Wu HY, Fraser-Smith EB, Walker KAM. Synthesis of 4β-cyanothymidine and analogs as potent inhibitors of HIV. Tetrahedron Lett 1992; 33(1): 37-40.
26. Sugimoto I, Shuto S, Mori S, Shigeta S, Matsuda A. Synthesis of 4β----branched thymidines as a new type of antiviral agent. Bioorg Med Chem Lett 1999; 9(3): 385-8.
27. Nomura M, Shuto S, Tanaka M, et al. Synthesis and biological activities of 4β----branched-chain sugar pyrimidine nucleosides J Med Chem 1999; 42(15): 2901-8.
28. Ohrui H, Kohgo S, Kitano K, et al. Synthesis of 4β-C-ethynyl-Darabino-and 4β-C-ethynyl-2β-deoxy----D-ribo-pentofuranosylpyrimidines and-purines and evaluation of their anti-HIV activity. J Med Chem 2000; 43(23); 4516-25.
29. Kodama E, Kohgo S, Kitano K, et al. 4β-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus varinats in vitro. Antimicrob Agents Chemother 2001; 45(5): 1539-46.
30. Nomura S, Shuto S, Tanaka M, et al. Synthesis and biological activity of 4β-alpha-C-branched-chain-sugar pyrimidine nucleosides J Med Chem 1999; 42(15); 2901-8.
31. Ohrui H, Kohgo S, Kitano K, et al. Synthesis of 4β-C-ethynyl beta-D-arabino and 4β-C-ethynyl-beta-D-ribo-pentofuranosylpyrimidine and-purines and evaluation of their anti-HIV activity. J Med Chem 2000; 43(23): 4516-25.
32. Haraguchi K, Takeda S, Tanaka H. Ring opening of 4β,5β-epoxynucleosides: a novel stereoselective entry to 4β-C-branched nucleosides. Org Lett 2003; 5(9): 1399-402.
33. Haraguchi K, Takeda S, Tanaka H, et al. Synthesis of a highly active new anti-HIV agent 2β,3β-didehydro-3β-deoxy-4β-ethynylthymidine. Bioorg Med Chem Lett 2003; 13(19): 3775-7.
34. Dutschman GE, Grill SP, Gullen EA, et al. Novel 4β-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 2004; 48(5): 1640-6.
35. Nitanda T, Wang X, Kumamoto H, et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2β,3β-didehydro-3β-deoxy-4β-ethynylthymidine in vitro. Antimicrob Agents Chemother 2005; 49(8): 3355-60.
36. Haraguchi K, Itoh Y, Takeda S, et al. Synthesis and anti-HIV activity of 4β-cyano-2β,3β-didehydro-3β-deoxythymidine. Nucleosdes Nucletides Nucleic Acids 2004; 23(4): 647-4.
37. Tanaka H, Haraguchi K, Kumamoto H, Baba M, Cheng YC. 4β-ethynylstavudine (4β-Ed4T) has potent anti-HIV activity with reduced toxicity and shows a unique activity profile against drug resistant mutants. Antiviral Chemistry & Chemotherapy 2005; 16(4): 217-21.
38. Kumamoto H, Haraguchi K, Tanaka H, et al. Synthesis of (±)-4β-ehtynyl-and 4β-cyano carbocyclic analogues of stavudine (d4T). Nucleosides Nucleotides Nucleic Acids 2005; 24(2): 73-83.
39. Kumamoto H, Haraguchi K, Ida M, et al. Synthesis of (±)-4β-ehtynyl-5β,5β-difluoro-2β,3β-dehydro-3β-deoxy-carbocyclic thymidine: a difluoromethylidene analogue of promising anti-HIV agent Ed4T. Tetrahedron 2009; 65(36): 7630-6.
40. Kumamoto H, Nakai T, Haraguchi K, et al. Synthesis and anti-HIV-1 activity of 4β-branched (-)-4β-thiostavudines. J Med Chem. 2006; 49(26): 7861-67.
41. Larder BA, Kemp SD, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 1989; 246(4934): 1155-8.
42. Schinazi RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37(4): 875-81.
43. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatmentexperienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr. 2003; 33(1): 15-21.
44. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004; 6(1): 22-33.
45. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. RT processivities in vitro, consistent with a potential fitness defect in vivo and the low prevalence of the K65R mutation among isolates from antiretroviral agent-experienced patients. Antimicrob Agents Chemother. 2002; 46(10): 3437-46.
46. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 1995; 92(6): 2398-402.
47. Delviks-Frankenberry, KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3β-azido-3β-deoxythymidine resistance. J Virol. 2007; 81(13): 6837-45.
48. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3β-azido-3β-deoxythymidine resistance. Proc Natl Acad Sci U S A. 2007; 104(1): 317-22.
49. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol. 2008; 82(7); 3261-70.
50. Yap SH, Sheen, CW, et al. N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. PLoS Med 2007; 4: e335.
51. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and-independent mechanisms J Biol Chem 2008; 283(32): 22222-32.
52. Longley MJ, Ropp PA, Lim SE, Copeland WC. Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 1998; 37(29): 10529-39.
53. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2β,3β-dideoxycytidine. J Biol Chem 1989; 264(20): 11934-7.
54. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991; 39(5): 625-8.
55. Yang G, Dutschman GE, Wang CJ, et al. Highly selective action of triphosphate metabolite of 4β-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res 2007; 73(3): 185-91.
56. Yang G, Wang J, Cheng Y, et al. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4β-ethynyl stavudine triphosphate. Antimicrob Agents Chemother 2008; 52(6): 2035-42.
57. Yang G, Paintsil E, Dutschman GE, et al. Impact of Novel HIV-1 Reverse Transcriptase Mutations, P119S and T165A on 4β-ethynylthymidine Analog Resistance Profile. Antimicrob Agents and Chemother 2009; 53(11); 4640-6.
58. Paintsil E, Dutschman GE, Hu R, et al. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2β,3β-didehydro-3β-deoxy-4β-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother 2007; 51(11): 3870-9.
59. Hsu CH, Hu R, Dutschman GE, et al. Comparison of the phosphorylation of 4'-ethynyl 2β,3β-dihydro-3β-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob Agents Chemother 2007; 51(5): 1687-93.
60. Wang X, Tanaka H, Baba M, Cheng YC. Study of the retention of metabolites of 4β-Ed4T, a novel anti-HIV-1 thymidine analog, in cells. Antimicrob Agents Chemother 2009; 53(8): 3317-24.
61. Paintsil E, Grill SP, Dutschman GE, Cheng YC. Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture. AIDS Res Ther 2009; 6: 5.
62. Zimmerman TP, Mahony WB, Prus KL. 3β-azido-3β-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 1987; 262(12): 5748-54.
63. Takuma Mastuda, Elijah Paintsil, Joel S. Ross, Jessica Schofield, Yung-Chi Cheng, Yasuo Urata. A Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601 (4β-Ed4T a Novel NRTI) in Healthy Subjects. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 2009.